What Is ADHD? Causes, Symptoms, Neuroscience, and Evidence-Based Treatment
A comprehensive, evidence-based explanation of ADHD — what it is, the neurobiological basis, the three presentations, how it is diagnosed in children and adults, what the research shows about causes, and what treatments are most effective.
What Is ADHD?
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and/or impulsivity that interfere with functioning and development. It is not a character flaw, a result of poor parenting, or a consequence of too much screen time — it is a well-established medical condition with a neurobiological basis, documented across cultures and continents.
ADHD is one of the most common neurodevelopmental disorders. The CDC estimates that approximately 11% of U.S. children (6–17 years) have received an ADHD diagnosis, and population-based studies suggest approximately 5% of children and 2.5% of adults worldwide meet diagnostic criteria. ADHD persists into adulthood in approximately 60–70% of those diagnosed in childhood — meaning millions of adults have ADHD, many of them undiagnosed. This article is educational. A qualified professional is needed for diagnosis and treatment planning.
The Three Presentations of ADHD
The DSM-5 describes ADHD in three presentations based on which symptoms predominate:
| Presentation | Dominant Symptoms | Notes |
|---|---|---|
| Predominantly Inattentive (ADHD-I) | Difficulty sustaining attention, easily distracted, forgetful, disorganized; low hyperactivity | Formerly called ADD; often undiagnosed, especially in girls and adults |
| Predominantly Hyperactive-Impulsive (ADHD-HI) | Fidgeting, excessive talking, difficulty waiting, acting without thinking | More common in younger children; often evolves to combined presentation |
| Combined Presentation (ADHD-C) | Both inattentive and hyperactive-impulsive symptoms | Most common presentation in diagnosed individuals |
The Neuroscience of ADHD
Dopamine and Norepinephrine Dysregulation
ADHD is fundamentally associated with dysregulation of the dopamine and norepinephrine systems in the brain's prefrontal cortex (PFC) and striatum. The PFC — responsible for executive functions including working memory, attention regulation, impulse control, and planning — requires optimal levels of these neurotransmitters to function effectively.
In ADHD, dopamine and norepinephrine signaling in the PFC is insufficient or improperly regulated. This impairs the PFC's ability to inhibit distracting stimuli, maintain task-relevant information in working memory, and suppress impulsive responses. The striatum — involved in reward processing and habit formation — shows reduced dopamine receptor density in ADHD, contributing to reward dysregulation and reduced intrinsic motivation for non-stimulating tasks.
This neurotransmitter model explains why stimulant medications are effective: they increase available dopamine and norepinephrine in the PFC and striatum, improving executive function.
Brain Structure and Function Differences
Neuroimaging research across thousands of participants has identified consistent brain differences in ADHD:
- Delayed cortical maturation: The most replicable finding. Shaw et al. (2007, PNAS) found that children with ADHD showed an average 3-year delay in cortical thickness maturation compared to typically developing controls, particularly in prefrontal regions. Crucially, the trajectory of development was normal — just delayed — which may explain why many adults show improvement in ADHD symptoms.
- Smaller subcortical volumes: A 2017 mega-analysis of 1,713 ADHD participants and 1,529 controls (Hoogman et al., Lancet Psychiatry) found significantly smaller volumes of the caudate, putamen, nucleus accumbens, amygdala, and hippocampus in ADHD. Effect sizes were small but consistent.
- Default Mode Network (DMN) dysregulation: The DMN — a network active during mind-wandering and rest — is normally suppressed during task performance. In ADHD, the DMN shows insufficient suppression during tasks, contributing to mind-wandering and attentional lapses.
Causes of ADHD
ADHD is one of the most heritable psychiatric conditions:
- Genetics: Heritability is approximately 74–80% based on twin studies — higher than for many other psychiatric conditions. ADHD runs strongly in families. Genome-wide association studies (GWAS) have identified over 75 common genetic variants associated with ADHD, most involved in dopaminergic and noradrenergic pathways.
- Prenatal exposures: Maternal smoking during pregnancy, alcohol use, and preterm birth are associated with increased ADHD risk. Exposure to environmental toxins (lead, organophosphate pesticides) has also been implicated.
- Non-genetic factors: Approximately 20–25% of ADHD variance is non-genetic. Environmental factors (including those above) interact with genetic predisposition.
- What does NOT cause ADHD: Scientific evidence does not support the popular belief that sugar consumption, excessive screen time, bad parenting, or vaccines cause ADHD. These factors may exacerbate symptoms but are not causes.
ADHD in Adults
Adult ADHD presents somewhat differently from childhood ADHD:
- Hyperactivity often manifests as internal restlessness rather than visible physical activity
- Inattention remains prominent: difficulty sustaining focus on lengthy tasks, missed details, chronic disorganization, difficulty completing projects
- Executive function deficits: time management problems, poor working memory, difficulty with planning and prioritization
- Emotional dysregulation: low frustration tolerance, mood lability, rejection-sensitive dysphoria
- Higher rates of comorbid conditions: depression (~53%), anxiety (~50%), substance use disorders (~15%), sleep disorders
Many adults with ADHD went undiagnosed in childhood — particularly women, who are more often inattentive-type and less visibly disruptive. Diagnosis in adulthood can be life-changing, explaining lifelong patterns of underachievement relative to measured intelligence and ability.
Evidence-Based Treatment
Stimulant Medications
Stimulants are the most evidence-supported pharmacological treatment for ADHD. Meta-analyses of hundreds of trials consistently find large effect sizes for reducing ADHD symptoms:
- Methylphenidate (Ritalin, Concerta, Vyvanse in some formulations): First-line in children; blocks dopamine and norepinephrine reuptake transporters
- Amphetamine-based medications (Adderall, Dexedrine, Vyvanse): Block reuptake and increase release of dopamine and norepinephrine; generally comparable efficacy to methylphenidate
Long-acting formulations (8–12 hours) are preferred over short-acting to avoid multiple school/work doses. Common side effects include appetite suppression, insomnia, and modest increases in heart rate and blood pressure — generally manageable with dose adjustment.
Non-Stimulant Medications
- Atomoxetine (Strattera): Selective norepinephrine reuptake inhibitor; non-controlled substance; takes 4–6 weeks for full effect; effective but less so than stimulants on average
- Guanfacine (Intuniv) and Clonidine (Kapvay): Alpha-2 agonists; improve prefrontal norepinephrine signaling; moderate efficacy; useful when stimulants are inappropriate or as adjuncts
Behavioral and Psychological Interventions
- Behavioral parent training (children): Teaching parents behavior management techniques; most effective in younger children
- Cognitive Behavioral Therapy (CBT) for adults: Addresses executive function deficits, organization, time management, and cognitive distortions; effective as adjunct to medication
- ADHD coaching: Practical support for organization, planning, and goal-setting
- School accommodations: Extended test time, reduced distraction testing environments, preferential seating — evidence-supported for academic performance